Browsing by Author "Natedao Kongyai"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without human immunodeficiency virus infection
    (2013-05-01) Kessara Pathanapitoon; Nattaporn Tesavibul; Pitipol Choopong; Sutasinee Boonsopon; Natedao Kongyai; Somsanguan Ausayakhun; Paradee Kunavisarut; Aniki Rothova; Chiang Mai University; Mahidol University; University Medical Center Utrecht; Erasmus University Medical Center
    Importance: Little attention has been paid to clinical features of cytomegalovirus (CMV) infections in individuals without human immunodeficiency virus (HIV). Objective: To describe the clinical manifestations and comorbidities of patients without HIV infection who have CMV-associated posterior uveitis or panuveitis. Design and Setting: Retrospective observational case series in an academic research setting. Participants: The medical records were reviewed of 18 patients (22 affected eyes) diagnosed as having posterior uveitis or panuveitis who had aqueous positive for CMV by polymerase chain reaction techniques. Main Outcome Measures: Demographic data, clinical manifestations, and associated systemic diseases were recorded. Results: Ocular features included focal hemorrhagic retinitis (n=13) and peripheral retinal necrosis (n=7). Two eyes had no focal retinal lesions but manifested vasculitis and vitritis. All patients exhibited vitreous inflammation. Inflammatory reactions in anterior segments developed in 14 of 22 eyes (64%). Retinal vasculitis was observed in 16 of 22 eyes (73%) and included mostly arteries (in 13 of 16 eyes [81%]). Eleven of 18 patients were taking immunosuppressive medications (5 for hematologic malignant diseases, 4 for systemic autoimmune diseases, and 2 following organ transplants). One additional patient was diagnosed as having non-Hodgkin lymphoma 3 months after the onset of CMV-associated panuveitis, and another patient had primary immunodeficiency disorder. Of the remaining 5 patients, 2 had diabetes mellitus, and 3 had no associated systemic diseases and exhibited no evidence of immune deficiency. Conclusions and Relevance: Cytomegalovirusassociated infections of posterior eye segments can develop in patients without HIV infection who have compromised immune function of variable severity but may occur also in individuals who have no evidence of immune insufficiency. Cytomegalovirus infections located in posterior eye segments in patients without HIV infection caused intraocular inflammatory reaction in all cases and demonstrated more variable clinical presentation than classic CMV retinitis observed in patients with HIV infection. © 2013 American Medical Association. All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Cytotoxic and anti-HIV-1 constituents of Gardenia obtusifolia and their modified compounds
    (2002-09-30) Patoomratana Tuchinda; Wilart Pompimon; Vichai Reutrakul; Manat Pohmakotr; Chalobon Yoosook; Natedao Kongyai; Samaisukh Sophasan; Kulawee Sujarit; Suchart E. Upathum; Thawatchai Santisuk; Mahidol University; Thailand Royal Forest Department
    5α-Cycloart-24-ene-3,23-dione (1), 5α-cycloart-24-ene-3,16,23-trione (2) and methyl 3,4-seco-cycloart-4(28),24-diene-29-hydroxy-23-oxo-3-oate (3), together with five known flavones 5,7,4′-trihydroxy-3,8-dimethoxyflavone (4), 5,7,4′-trihydroxy-3,8,3′-tri-methoxyflavone (5), 5,7,4′-trihydroxy-3,6,8-trimethoxyflavone (6), 5,4′-dihydroxy-3,6,7,8-tetramethoxyflavone (7) and 5,3′-dihydroxy-3,6,7,8,4′-pentamethoxyflavone (8) have been isolated from the leaves and twigs of Gardenia obtusifolia. The structures were assigned on the basis of spectroscopic methods. Compounds 3-8 and some of the modified compounds showed significant cytotoxic activities in several mammalian cell lines, especially 8 and its diacetate 21 which exhibited potent cytotoxicities (compound 8: P-388 0.05μg/mL, KB 0.09μg/mL, BCA-1 0.63μg/mL, Lu-1 0.09μg/mL, ASK 0.70μg/mL; its diacetate: P-388 0.27μg/mL, KB 0.06μg/mL, BCA-1 0.53μg/mL, Lu-1 0.49μg/mL). It was also found that 5, 8 and 21 showed antimitotic acitivity in the ASK assay. Compounds 2, 4, 6, 7 and some of the modified compounds displayed interesting anti-HIV activity in the syncytium assay, but were inactive or exhibited weak activity in the HIV-1 RT assay; while compound 3 was found to be active in the HIV-1 RT assay (99.9 % inhibition at 200μg/mL), but cytotoxic in the syncytium assay. © 2002 Elsevier Science Ltd. All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Lack of association between adverse pregnancy outcomes and zika antibodies among pregnant women in thailand between 1997 and 2015
    (2021-08-01) Nicole Ngo-Giang-huong; Charline Leroi; Dahlene Fusco; Tim R. Cressey; Nantawan Wangsaeng; Nicolas Salvadori; Natedao Kongyai; Wasna Sirirungsi; Marc Lallemant; Prasert Auewarakul; Woottichai Khamduang; Gonzague Jourdain; Siriraj Hospital; Université de Montpellier; Tulane University School of Medicine; Chiang Mai University; Associated Medical Sciences (AMS)-CMU IRD Research Collaboration
    Data about Zika virus infection and adverse pregnancy outcomes in Southeast Asia are scarce. We conducted an unmatched case-control study of Zika virus (ZIKV) serology in pregnant women enrolled in human immunodeficiency virus (HIV) or hepatitis B virus (HBV) perinatal prevention trials between 1997 and 2015 in Thailand. Case and control groups included women with and without adverse pregnancy outcomes. Plasma samples collected during the last trimester of pregnancy were tested for ZIKV IgG/IgM and Dengue IgG/IgM (Euroimmun, AG, Germany). Case newborn plasma samples were tested for ZIKV IgM and ZIKV RNA (Viasure, Spain). The case group included women with stillbirth (n = 22) or whose infants had microcephaly (n = 4), a head circumference below the first percentile (n = 14), neurological disorders (n = 36), or had died within 10 days after birth (n = 11). No women in the case group were positive for ZIKV IgM, and none of their live-born neonates were positive for ZIKV IgM or ZIKV RNA. The overall ZIKV IgG prevalence was 29%, 24% in the case and 34% in the control groups (Fisher’s exact test; p = 0.13), while the dengue IgG seroprevalence was 90%. Neither neonatal ZIKV infections nor ZIKV-related adverse pregnancy outcomes were observed in these women with HIV and/or HBV during the 18-year study period.